CytoMed Therapeutics (GDTC) Other Non-Current Liabilities (2023 - 2025)

CytoMed Therapeutics (GDTC) has disclosed Other Non-Current Liabilities for 3 consecutive years, with $19338.8 as the latest value for Q4 2025.

  • Quarterly Other Non-Current Liabilities rose 115.36% to $19338.8 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $19338.8 through Dec 2025, up 115.36% year-over-year, with the annual reading at $19491.0 for FY2025, 122.93% up from the prior year.
  • Other Non-Current Liabilities hit $19338.8 in Q4 2025 for CytoMed Therapeutics, up from $8980.0 in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $108595.1 in Q4 2023 to a low of $8980.0 in Q4 2024.
  • Historically, Other Non-Current Liabilities has averaged $45638.0 across 3 years, with a median of $19338.8 in 2025.
  • Biggest five-year swings in Other Non-Current Liabilities: crashed 91.73% in 2024 and later surged 115.36% in 2025.
  • Year by year, Other Non-Current Liabilities stood at $108595.1 in 2023, then plummeted by 91.73% to $8980.0 in 2024, then soared by 115.36% to $19338.8 in 2025.
  • Business Quant data shows Other Non-Current Liabilities for GDTC at $19338.8 in Q4 2025, $8980.0 in Q4 2024, and $108595.1 in Q4 2023.